Ximena Baez-Navarro, Nadine S van den Ende, Anh H Nguyen, Renata Sinke, Pieter Westenend, Johannes Bastiaan van Brakel, Claudia Stobbe, Johan Westerga, Carolien H M van Deurzen
Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy has demonstrated promising results in TNBC, due to its immunogenicity. In addition, a novel antibody-drug conjugate, namely, trastuzumab-deruxtecan, has shown effectiveness in TNBC patients with low-HER2 expression (HER2-low). These novel treatment options raise the question about the potential association between the density of stromal tumor-infiltrating lymphocytes (sTILs) and the level of HER2 expression...
March 11, 2024: Breast Cancer Research: BCR